title: Long-term efficacy and safety of tocilizumab in giant cell arteritis and large vessel vasculitis.
abstract: Giant cell arteritis (GCA) is a chronic systemic vasculitis affecting large-sized and medium-sized vessels. Glucocorticoids are currently the mainstay of treatment for GCA and associated large vessel vasculitis (LVV) but are associated with frequent adverse events. Methotrexate has only demonstrated a modest benefit while anti-TNF biological agents (infliximab and etanercept) have been inefficacious. Elevated levels of interleukin-6 (IL-6), a proinflammatory cytokine, has been associated with GCA. Tocilizumab (TCZ), a humanised antihuman IL-6 receptor antibody, has been used successfully in several reports as a treatment for GCA and LVV. We report the potentially long-term successful use of TCZ in 8 cases of refractory LVV. All of our patients achieved a good clinical response to TCZ and C reactive protein reduced from an average of 70.3 to 2.5. In all cases, the glucocorticoid dose was reduced, from an average of 24.6 mg prednisolone prior to TCZ treatment to 4.7 mg, indicating that TCZ may enable a reduction in glucocorticoid-associated adverse events. However, regular TCZ administration was needed for disease control in most cases. TCZ was discontinued in one case due to the development of an empyema indicating the need for careful monitoring of infection when using this treatment.
authors.affiliation: Rheumatology Department , Southend Hospital, Prittlewell Chase , Westcliff-on-sea, Essex , UK.
authors.forename: Jobie
authors.initials: J
authors.lastname: Evans
authors.affiliation: Rheumatology Department , Southend Hospital, Prittlewell Chase , Westcliff-on-sea, Essex , UK.
authors.forename: Lauren
authors.initials: L
authors.lastname: Steel
authors.affiliation: Rheumatology Department , Southend Hospital, Prittlewell Chase , Westcliff-on-sea, Essex , UK.
authors.forename: Frances
authors.initials: F
authors.lastname: Borg
authors.affiliation: Rheumatology Department, Southend Hospital, Prittlewell Chase, Westcliff-on-sea, Essex, UK; University of Essex, Colchester, UK; Anglia Ruskin University,  Essex, UK.
authors.forename: Bhaskar
authors.initials: B
authors.lastname: Dasgupta
keywords: DMARDs (biologic); Giant Cell Arteritis; Systemic vasculitis; Treatment
references.citation: Arthritis Care Res (Hoboken). 2012 Nov;64(11):1720-9
references.pmid: 22674883
references.citation: J Rheumatol. 2011 Sep;38(9):2080-1
references.pmid: 21885526
references.citation: Semin Arthritis Rheum. 2015 Jun;44(6):717-23
references.pmid: 25697557
references.citation: Arthritis Rheum. 1993 Sep;36(9):1286-94
references.pmid: 8216422
references.citation: Rheumatology (Oxford). 2010 Aug;49(8):1594-7
references.pmid: 20371504
references.citation: Clin Exp Rheumatol. 2014 May-Jun;32(3 Suppl 82):S76-8
references.pmid: 24854376
references.citation: Arthritis Rheum. 2003 Oct 15;49(5):703-8
references.pmid: 14558057
references.citation: Ann Rheum Dis. 2011 Oct;70(10 ):1874-5
references.pmid: 21515917
references.citation: BMJ Case Rep. 2011 Jun 30;2011:null
references.pmid: 22693300
references.citation: Ann Rheum Dis. 2008 May;67(5):625-30
references.pmid: 18086726
references.citation: Br J Rheumatol. 1990 Dec;29(6):456-8
references.pmid: 2124160
references.citation: Ann Rheum Dis. 2000 Nov;59 Suppl 1:i21-7
references.pmid: 11053081
references.citation: Arthritis Rheum. 1999 Feb;42(2):311-7
references.pmid: 10025926
references.citation: Swiss Med Wkly. 2011 Jan 17;141:w13156
references.pmid: 21243547
references.citation: Arthritis Rheum. 2001 Dec;44(12):2933-5
references.pmid: 11762955
references.citation: Rheumatology (Oxford). 2012 Jan;51(1):151-6
references.pmid: 22075063
references.citation: Arthritis Rheum. 2007 Aug;56(8):2789-97
references.pmid: 17665429